ArticleJournal of medical primatology2011
A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells.
Article in Journal of medical primatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- CARs: Beyond T Cells and T Cell-Derived Signaling Domains.International journal of molecular sciences · 2020Review
- Review
- Role of memory T cell subsets for adoptive immunotherapy.Seminars in immunology · 2016Review
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.Leukemia · 2016Article
- Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2015Review
- Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.Cancer immunology research · 2015Article
- Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.Immunological reviews · 2014Review
- Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection.Journal of medical primatology · 2013Article
- CARs in chronic lymphocytic leukemia -- ready to drive.Current hematologic malignancy reports · 2013Review
- Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques.PloS one · 2013Article
- Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity.Frontiers in bioscience (Scholar edition) · 2012Review
- Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy.Current opinion in immunology · 2011Review
- Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundAdoptive immunotherapy with antigen-specific effector T-cell (T(E) ) clones is often limited by poor survival of the transferred cells. We describe here a Macaca nemestrina model for studying transfer of T-cell immunity.
methodsWe derived, expanded, and genetically marked CMV-specific CD8(+) T(E) clones with surface markers expressed on B cells. T(E) cells were adoptively transferred, and toxicity, persistence, retention of introduced cell-surface markers, and phenotype of the persisting T cells were evaluated.
resultsCD8(+) T(E) clones were efficiently isolated from distinct memory precursors and gene-marking with CD19 or CD20 permitted in vivo tracking by quantitative PCR. CD19 was a more stable surface marker for tracking cells in vivo and was used to re-isolate cells for functional analysis. Clonally derived CD8(+) T(E) cells differentiated in vivo to phenotypically and functionally heterogeneous memory T-cell subsets.
conclusionsThese studies demonstrate the utility of Macaca nemestrina for establishing principles for T-cell therapeutics applicable to humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.